Financial Performance & Growth - Haemonetics reported FY'22 revenue of $351 million for Plasma, $299 million for Blood Center, and $323 million for Hospital business units[7] - The company experienced a 14% GAAP revenue growth in FY'22, with organic revenue growth at 7%[44] - Haemonetics is targeting mid-teens CAGR in adjusted diluted EPS[46] Market & Strategy - The source plasma market has a FY'20 Total Addressable Market (TAM) of approximately $800 million and is growing at 8-10%[13] - The plasma-derived therapies market has a FY'20 TAM of approximately $27 billion, with Immunoglobulins accounting for 55%[14] - Haemonetics aims to compete in winning segments and geographies to achieve leading positions, focusing on revenue, profitability, and cash flow growth[10] Operational Excellence - The Operational Excellence Program is projected to yield gross savings of $115 million - $125 million from FY'20 through FY'25[39] - The Operational Excellence Program is expected to achieve approximately 30% net savings[39]

Financial Data and Key Metrics Changes - The company reported first quarter organic revenue growth of 17% and adjusted earnings per diluted share of $0.58, an increase of 16% compared to the first quarter of the prior year [8][32] - Adjusted gross margin reached a record 55.2%, reflecting a 50 basis point margin expansion year-on-year, primarily driven by volume and mix [25][26] - Adjusted operating income was $44.9 million, an increase of 18%, with an adjusted operating margin of 17.2%, up 60 basis points compared to the same period in fiscal '22 [29] Business Line Data and Key Metrics Changes - Plasma revenue increased by 44% in the first quarter, with North America experiencing 47% growth, driven by both volume and price [12][13] - Hospital revenue grew by 15%, with Vascular Closure revenue increasing by 36% [17][18] - Hemostasis Management revenue grew by 6%, while Transfusion Management revenue increased by 21% [19][20] - Blood Center revenue declined by 7%, with Apheresis revenue down 13% due to unfavorable order timing and staffing shortages [22][23] Market Data and Key Metrics Changes - North America remains the largest market for Plasma, representing over 90% of total Plasma revenue, with a 40% growth in U.S. plasma collection volume excluding CSL [12][13] - Strong double-digit collections growth was also observed in Europe [14] - The company is experiencing challenges in Europe due to a tough comparison from the previous year, particularly in Hemostasis Management [19] Company Strategy and Development Direction - The company is focused on advancing market leadership and delivering robust revenue and adjusted EPS growth over the next several years [8] - Investments are being made to distinguish technologies and create new opportunities for customers, particularly in the hospital segment [10] - The operational excellence program is on track to deliver significant savings and efficiency improvements [29][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of plasma collections and the performance of the hospital business despite ongoing challenges [38] - The macroeconomic environment continues to exert downward pressure on margins, but the company remains optimistic about growth and margin expansion [30][31] - Future guidance for adjusted earnings per diluted share has been updated to a range of $2.60 to $2.90 [33] Other Important Information - The company announced a new 3-year $300 million share repurchase authorization to offset shareholder dilution [25] - Cash on hand at the end of the first quarter was $214.9 million, down from the beginning of the fiscal year [34] - Free cash flow guidance for fiscal '23 remains unchanged at $100 to $130 million [36] Q&A Session Summary Question: Insights on Plasma growth and mature centers - Management noted that mature centers are showing improvement, contributing to the positive trend in plasma collections, which has exceeded historical averages [44][46] Question: Guidance on sales and EPS - The increase in sales guidance is primarily driven by macroeconomic headwinds, including inflation and foreign exchange impacts [48] Question: Clarification on Plasma guidance - The increase in organic guidance includes contributions from both volume and price, with ongoing upgrades to technology [51] Question: Hospital performance breakdown - Vascular Closure is the fastest-growing segment, while Hemostasis Management faced challenges due to tough comparisons from the previous year [54] Question: Future growth confidence - Management expressed confidence in the ability to grow both top and bottom lines in fiscal 2024, driven by strong trends in plasma and hospital segments [59] Question: Capital allocation and buyback timing - The buyback is seen as a substantial commitment, balancing between organic growth investments and share repurchase [101]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q For the quarterly period ended: July 2, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 2, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpora ...

Haemonetics Corporation (NYSE:HAE) Q4 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D’Arecca - CFO Conference Call Participants Larry Solow - CJS Securities Drew Ranieri - Morgan Stanley Andrew Cooper - Raymond James Mike Matson - Needham & Company David Turkaly - JMP Securities Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Haemonetics Corporation Fourth Quarter Fiscal 2022 E ...

Haemonetics Corporation Raymond James 43rd Institutional Investors Conference March 7-8, 2022 © 2022 Haemonetics Corporation Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the "Company"), including plans or objectives rel ...

Haemonetics Corporation (NYSE:HAE) Q3 2022 Results Conference Call February 8, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR Christopher Simon - President, CEO William Burke - CFO Conference Call Participants Zach Weiner - Jefferies Andrew Cooper - Raymond James Mike Matson - Needham & Company Drew Ranieri - Morgan Stanley Larry Solow - CJS Securities Operator Good day, and thank you for standing by. Welcome to the Haemonetics Corporation's Third Quarter Fiscal 2022 Earnings Call. [Operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended: January 1, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (781) 848-7100 (Registrant's telephone number, including are ...

Haemonetics Corporation (NYSE:HAE) Q2 2022 Earnings Conference Call November 9, 2021 8:00 AM ET Company Participants Olga Guyette - Director, Investor Relations Chris Simon - President and Chief Executive Officer Bill Burke - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Jefferies Andrew Cooper - Raymond James Drew Ranieri - Morgan Stanley Mike Matson - Needham & Company Operator Good morning ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (State or other jurisdiction of incorporation or organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 2, 2021 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-28822 ...